[go: up one dir, main page]

AR013981A1 - Terapia de progestina con hemorragia controlada - Google Patents

Terapia de progestina con hemorragia controlada

Info

Publication number
AR013981A1
AR013981A1 ARP980105256A ARP980105256A AR013981A1 AR 013981 A1 AR013981 A1 AR 013981A1 AR P980105256 A ARP980105256 A AR P980105256A AR P980105256 A ARP980105256 A AR P980105256A AR 013981 A1 AR013981 A1 AR 013981A1
Authority
AR
Argentina
Prior art keywords
therapy
hemorragy
progestine
controlled
progestin
Prior art date
Application number
ARP980105256A
Other languages
English (en)
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of AR013981A1 publication Critical patent/AR013981A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion explica que el suministro de progestina en forma diaria, cíclica por vía vaginal puede ser usado para proporcionar unahemorragia premenopáusica predecible, regular durante la terapia de sustitucion de hormonas. La presenteinvencion también describe que la administracionconstante de progestina en un polímero de ácido policarboxílico entrecruzado no soluble al agua y que se hincha con el agua puede ser empleada para mantener laamenorrea. Cualquiera de los regímenes sea compana con una disminucion significativa de los efectos colaterales adversos.
ARP980105256A 1997-10-21 1998-10-22 Terapia de progestina con hemorragia controlada AR013981A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6348597P 1997-10-21 1997-10-21
US09/170,326 US6306914B1 (en) 1997-10-21 1998-10-13 Progestin therapy for maintaining amenorrhea

Publications (1)

Publication Number Publication Date
AR013981A1 true AR013981A1 (es) 2001-01-31

Family

ID=26743461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105256A AR013981A1 (es) 1997-10-21 1998-10-22 Terapia de progestina con hemorragia controlada

Country Status (19)

Country Link
US (3) US6306914B1 (es)
EP (1) EP1032399A1 (es)
JP (1) JP2003535015A (es)
KR (1) KR100581308B1 (es)
CN (1) CN1147301C (es)
AR (1) AR013981A1 (es)
AU (1) AU742166C (es)
BR (1) BR9813262A (es)
CA (2) CA2307615A1 (es)
HU (1) HUP0004133A3 (es)
IL (1) IL135742A (es)
MX (1) MXPA00003972A (es)
MY (1) MY121743A (es)
NO (1) NO326856B1 (es)
NZ (1) NZ504066A (es)
PE (1) PE121799A1 (es)
RO (1) RO121319B1 (es)
RU (2) RU2261099C2 (es)
WO (1) WO1999020282A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
AU2002348272B2 (en) * 2001-12-05 2008-07-31 Theramex HQ UK Limited Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP1513547A4 (en) * 2002-05-23 2009-11-04 Michael F Holick USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY
WO2004058110A2 (en) * 2002-12-24 2004-07-15 Ovion, Inc. Contraceptive device and delivery system
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
DK1635843T3 (da) * 2003-06-25 2009-05-04 Bayer Schering Pharma Ag Terapi, der omfatter dienogest for hormonerstatning og depression
CN101001631B (zh) * 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
CA2569738A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
JP2009521533A (ja) * 2005-12-27 2009-06-04 デュラメド ファーマシューティカルズ インコーポレーティッド 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法
EP1983998A2 (en) * 2006-01-20 2008-10-29 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
US9693953B2 (en) * 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
GB0616444D0 (en) * 2006-08-18 2006-09-27 Reckitt Benckiser Nv Detergent composition
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2697369C1 (ru) * 2018-12-21 2019-08-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113288865B (zh) * 2021-06-28 2022-03-08 浙江仙琚制药股份有限公司 一种黄体酮阴道凝胶剂的制备方法
CN114983929A (zh) * 2022-05-16 2022-09-02 安徽万邦医药科技股份有限公司 一种稳定的黄体酮缓释凝胶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002092A1 (en) 1983-11-14 1985-05-23 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
USD345211S (en) 1992-04-06 1994-03-15 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
USD375352S (en) 1994-03-14 1996-11-05 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products

Also Published As

Publication number Publication date
US20010031747A1 (en) 2001-10-18
CN1147301C (zh) 2004-04-28
CN1282250A (zh) 2001-01-31
RU2005101612A (ru) 2006-07-10
HUP0004133A3 (en) 2001-09-28
NO20002084L (no) 2000-06-21
MY121743A (en) 2006-02-28
KR20010031299A (ko) 2001-04-16
RO121319B1 (ro) 2007-03-30
IL135742A (en) 2004-09-27
US6593317B1 (en) 2003-07-15
NO326856B1 (no) 2009-03-02
NZ504066A (en) 2002-11-26
US6306914B1 (en) 2001-10-23
AU742166B2 (en) 2001-12-20
EP1032399A1 (en) 2000-09-06
HUP0004133A2 (hu) 2001-05-28
NO20002084D0 (no) 2000-04-19
AU742166C (en) 2005-07-14
RU2261099C2 (ru) 2005-09-27
AU1191499A (en) 1999-05-10
IL135742A0 (en) 2001-05-20
CA2649671A1 (en) 1999-04-29
BR9813262A (pt) 2000-08-22
KR100581308B1 (ko) 2006-05-22
JP2003535015A (ja) 2003-11-25
MXPA00003972A (es) 2004-04-21
CA2307615A1 (en) 1999-04-29
PE121799A1 (es) 1999-12-17
WO1999020282A1 (en) 1999-04-29
RU2330667C2 (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
AR013981A1 (es) Terapia de progestina con hemorragia controlada
CO4290332A1 (es) Nuevo metodo de suministro de progesterona y el efecto del mismo
ES2053105T3 (es) Emulsion formadora de peliculas que contiene yodo y metodos de uso.
ES2193146T3 (es) Composicion farmaceutica con inicio de liberacion y velocidad de liberacion controlados.
AR006484A1 (es) Composición farmacéutica con efecto anestésico, uso de esta composición para la fabricación de medicamentos, y proceso para la fabricación de esta composición .
ES2111547T3 (es) Comprimido de liberacion prolongada.
ES2163554T3 (es) Neumatico que comprende cables circunferenciales, para anclar la carcasa, y procedimiento de preparacion de dichos cables.
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
AR022148A1 (es) ARTíCULO ABSORBENTE Y MÉTODO PARA FABRICAR UNA ESTRUCTURA ABSORBENTE.
AR032352A1 (es) Composicion farmaceutica bioadhesiva de hidratacion gradual y su uso en la fabricacion de un medicamento para la administracion de testosterona y terbutalina a un mamifero a traves de una superficie de mucosa.
CO5150210A1 (es) Tratamiento de bph con agentes elevadores del cgmp
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
ES2116451T3 (es) Dispensador de fluidos.
ES2038807T3 (es) Protesis dilatable para correcciones de miodistrofias.
GB8711058D0 (en) Combination
CO5631449A2 (es) Nuevos esteres de etonogestrel
FI833018A0 (fi) Laekemedelsblandad suppositorium
ES2173485T3 (es) Anestesico local para uso externo.
SE8800025D0 (sv) Bioadhesive suppository pharmaceutical preparations
CO4960650A1 (es) Composicion con agente emulsificador de copolimero reticulado de acrilato /c10/c30 alquilo acrilato
DE60127839D1 (de) Pflaster mit 4-biphenylessigsäure
ES2125354T3 (es) Composicion a base de tandospirona o de sus analogos.
ES2162433T3 (es) Procedimiento para el tratamiento del clinker de cemento.
ES2090167T3 (es) Uso topico de glicosaminoglicanos en la prevencion y el tratamiento de enfermedades que afectan al tracto vaginal cervical.
BR9813953A (pt) Sistema de afixação de válvula de descarga.

Legal Events

Date Code Title Description
FB Suspension of granting procedure